Soluble Lutein Inhibits Cholinesterase and Reduces Ultraviolet Radiation-Induced Inflammation and Immunosuppression: In vitro Model
Morristown, N.J. – OmniActive Health Technologies is presenting a poster on the study Soluble Lutein Inhibits Cholinesterase and Reduces Ultraviolet Radiation-Induced Inflammation and Immunosuppression: In vitro Model at The Macular Carotenoids Conference’s (MCC) annual meeting, taking place from July 8th – 10th at Downing College, Cambridge University (UK). The study was conducted by Vijaya Juturu Ph.D., F.A.C.N., Manager of Global Scientific and Clinical Affairs, Khadija Ghanam, Ph.D. Clinical Nutritional Biochemist, and Jayant Deshpande, Ph.D., CTO—all of OmniActive Health Technologies.
This in vitro study evaluated the effect of the macular carotenoids— lutein and the two zeaxanthin isomers (Lutemax 2020®)— on cholinesterase activity and antioxidant enzymes in response to ultraviolet (UV) irradiation. Lutein and zeaxanthin isomers may ameliorate the effects of mild UV irradiation on Retinal Pigment Epitheleal (RPE) cells, as shown by expression of genes involved in cell proliferation, inflammation, immune function and wound healing. Lutein and zeaxanthin isomers inhibited cholinesterase activity and enhanced catalase activity in cells exposed to mild irradiation. These results suggest inhibition of cholinesterase enzyme and enhancing antioxidant enzymes may have several therapeutic applications such as neurodegenerative disorders and myasthenia gravis.
“We are excited to see from this Lutemax® 2020 study these new insights into the critical role that lutein and zeaxanthin isomers (RR-zeaxanthin and RS (meso)-zeaxanthin) may play in eye health, specifically as potent antioxidants and antiinflammatory agents protecting retinal tissue,” stated Jayant Desphande, Chief Technology Officer, OmniActive Health Technologies.
OmniActive— leaders in scientifically-validated, premium ingredients—offers the most comprehensive line of macular carotenoids. The study Soluble Lutein Inhibits Cholinesterase and Reduces Ultraviolet Radiation-Induced Inflammation and Immunosuppression: In vitro Model is a product of the OmniActive’s robust scientific program as well as another significant addition to the growing science on the macular carotenoids.
About the Macular Carotenoids Conference
This three day conference brings together the premier researchers to explore up-to-date and evidence-based hypotheses, as well as to further support research data into the role of the macular carotenoids in age-related macular degeneration (AMD), vision, and cognitive function. MCC was founded by The Howard Foundation—a world-recognized charitable trust established in 1982—which provides funding for biomedical research in key areas of health including nutrition. Highlights of The Howard Foundation include research into the means of relieving malnutrition, especially in undeveloped countries.
About OmniActive Health Technologies
OmniActive Health Technologies (www.omniactives.com) offers a range of quality ingredients, which are innovative and scientifically validated for dietary supplementation, nutritional fortification, functional food/beverage, coloring, flavor enhancement and personal care applications. The company addresses complex challenges for customers in the dietary supplement, food and beverage space using technology-driven, sustainable solution with application support within a global regulatory framework. Whether looking for a new ingredient to add to a finished product, or an ingredient solution to enhance an existing ingredient, you will find unmatched innovation at OmniActive.
Core products include carotenoids, plant extracts and specialty functional ingredients. OmniActive leverages international R&D strengths to deploy an array of state of the art manufacturing technologies in extraction, purification, isolation and delivery of nutritional actives. The company’s manufacturing operations are located at multiple sites in India and are cGMP and HACCP system compliant.